Ondansetron B. Braun

Ondansetron, the active ingredient in Ondansetron B. Braun, is a 5-HT3 receptor antagonist presented as an intravenous solution for injection use. It is employed to prevent and treat nausea and vomiting caused by chemotherapy, radiotherapy, and surgery in adult and pediatric patients.

GNH USA supplies Ondansetron B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used to control nausea and vomiting across several clinical pathways.

Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes. Radiotherapy‑induced nausea and vomiting: helps control symptoms during and after treatment. Postoperative nausea and vomiting: prevents nausea and vomiting following surgical procedures.

Ondansetron may cause adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache - Constipation - Dizziness - Injection site pain

Serious or Rare Side Effects: - QT interval prolongation - Severe allergic reactions (anaphylaxis) - Serotonin syndrome (rare)

When using Ondansetron, clinicians should observe several safety measures.

Assess cardiac history: obtain baseline ECG in patients with known cardiac disease. Monitor electrolytes: correct hypokalemia and hypomagnesemia before administration. Use caution with other QT‑prolonging drugs. Avoid use in patients with known hypersensitivity to ondansetron or its excipients. Pregnancy and lactation: weigh benefits against potential risks; consult obstetric guidance. Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze.

Ondansetron can interact with other medicines, requiring attention to potential risks.

Major Interactions (Avoid): - Other QT‑prolonging agents (e.g., quinidine, amiodarone): may increase risk of cardiac arrhythmia. - Apomorphine: concomitant use can cause severe hypotension and loss of consciousness. - Serotonergic drugs (e.g., SSRIs, MAO inhibitors) when combined with high doses may increase risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Anticholinergic agents: may enhance anticholinergic side effects.